Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

If you've ever dined at Cracker Barrel, there's a good chance that you've tried the savory, cheesy delight that is their hash ...

Twitter: @joefromseattle1 Donations: <a href=" My band: <a href=" Doofus Discord: <a href=" Get a discount on a sweet mouse pad at novaproducts.gg with code "JOEFROMSEATTLE" Check out Curbside Anthem ...

TESCO shoppers are racing to bag a stylish waterproof jacket that looks just like a designer version from John Lewis – but ...

A MotoGP paddock insider believes a Formula 1 ‘Drive to Survive’-style docuseries is inevitable after F1 owners Liberty Media ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Glencore Earnings Fall on Lower Coal Prices, Copper Production Challenges The commodities giant said the results reflect lower coal prices and a drop in copper production following operational ...